PP
IMVT icon

PDT Partners’s Immunovant IMVT Stock Holding History

PDT Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,779
Closed -$183K – 615
2023
Q1 		$183K Buy
11,779
+90
+0.8% +$1.56K 0.02% 507
2022
Q4 		$207K Sell
11,689
-506
-4% -$6.37K 0.03% 532
2022
Q3 		$68K Sell
12,195
-123,033
-91% -$601K 0.01% 800
2022
Q2 		$527K Hold
135,228
– – 0.05% 587
2022
Q1 		$745K Buy
135,228
+26,090
+24% +$162K 0.06% 469
2021
Q4 		$930K Buy
+109,138
New +$901K 0.07% 379
2021
Q3 		– Sell
-135,700
Closed -$1.43M – 831
2021
Q2 		$1.43M Buy
+135,700
New +$1.89M 0.09% 312

Other funds holding IMVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

PDT Partners's IMVT Position: Q2 2023 in Review

PDT Partners sold out of Immunovant (IMVT) in Q2 2023, closing a stake of 11,779 shares — an estimated $183K sold.

PDT Partners first reported a position in IMVT in Q2 2021 and held it in 7 quarters. The position peaked at $1.43M in Q2 2021. 147 funds tracked by Wall St. Rank hold IMVT as of Q2 2023.

  • PDT Partners reported no remaining Immunovant position as of Q2 2023 after selling out during the quarter.
  • PDT Partners sold 11,779 Immunovant shares in Q2 2023, an estimated $183K.
  • PDT Partners first reported a position in Immunovant in Q2 2021 and held it in 7 quarters.
  • PDT Partners's Immunovant position peaked at $1.43M in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Immunovant as of Q2 2023.

Based on PDT Partners's 13F filing for Q2 2023, filed 14 Aug 2023.